Ash Biotech has unique, world-class know-how and intellectual property in the areas of high-content screening, high-throughput screening, and antibody (and antibody-like) drug discovery. We commercialise our technology through collaborations with biotech and pharma companies, and via productisation of key technology assets (see PhenoSight, a technology platform for high-content screening and assay-development, and related Products).